The english version of the website of the School of Medicine is under development


Pharmacotherapy of obesity: Available medications and drugs under investigation.

TitlePharmacotherapy of obesity: Available medications and drugs under investigation.
Publication TypeJournal Article
Year of Publication2019
AuthorsPilitsi, E., Farr O. M., Polyzos S. A., Perakakis N., Nolen-Doerr E., Papathanasiou A-E., & Mantzoros C. S.
Date Published2019 Mar

Obesity is a chronic disease with a continuously rising prevalence that currently affects more than half a billion people worldwide. Energy balance and appetite are highly regulated via central and peripheral mechanisms, and weight loss triggers a homeostatic response leading to weight regain. Lifestyle and behavioral modifications are the cornerstones of obesity management; however, they often fail to achieve or sustain long-term weight loss. Pharmacotherapy added onto lifestyle modifications results in an additional, albeit limited, weight reduction. Regardless, this weight reduction of 5-10% conveys multiple cardiovascular and metabolic benefits. In this review, evidence on the food and drug administration (FDA)-approved medications, i.e., orlistat, lorcaserin, phentermine/topiramate, liraglutide and naltrexone/bupropion, is summarized. Furthermore, anti-obesity agents in the pipeline for potential future therapeutic use are presented.

Alternate JournalMetab. Clin. Exp.
PubMed ID30391259


Secretariat of the School of Medicine


Schoole of Medicince presence in social networks
Follow Us or Connect with us.